Tubocurarine chloride

From Wikipedia, the free encyclopedia
  (Redirected from Tubocurarine)
Jump to: navigation, search
Tubocurarine chloride
Tubocurarine.svg
Tubocurarine-3D-sticks.png
Systematic (IUPAC) name
6,6'-dimethoxy-2,2,2',2'-tetramethyltubocuraran-2,2'-diium-7',12'-diol
Clinical data
AHFS/Drugs.com International Drug Names
MedlinePlus a682860
Pregnancy
category
  • D
Legal status
  • World wide Rx-only medication
Routes of
administration
IV
Pharmacokinetic data
Bioavailability 100% (IV)
Protein binding 50%
Biological half-life 1-2 hours
Identifiers
CAS Registry Number 57-95-4 YesY (chloride hydrochloride)
6989-98-6 (chloride hydrochloride pentahydrate)
ATC code M03AA02
PubChem CID: 6000
IUPHAR/BPS 2294
DrugBank DB01199 YesY
ChemSpider 5778 YesY
UNII 900961Z8VR YesY
ChEBI CHEBI:9774 YesY
ChEMBL CHEMBL1687 YesY
Chemical data
Formula C37H42Cl2N2O6
Molecular mass 624.765 g/mol
 N (what is this?)  (verify)

Tubocurarine (also known as d-tubocurarine or DTC) is a toxic alkaloid historically known for its use as an arrow poison. In the mid-1900s, it was used in conjunction with an anesthetic to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is now rarely used as an adjunct for clinical anesthesia because safer alternatives, such as cisatracurium and rocuronium, are available.

History[edit]

Tubocurarine is a naturally occurring mono-quaternary alkaloid obtained from the bark of the South American plant Chondrodendron tomentosum, a climbing vine known to the European world since the Spanish conquest of South America. Curare had been used as a source of arrow poison by South American natives to hunt animals, and they were able to eat the animals' contaminated flesh subsequently without any adverse effects because tubocurarine cannot easily cross mucous membranes. Tubocurarine is thus effective only if given parenterally, as demonstrated by Bernard, who also showed the site of its action was at the neuromuscular junction.[1] Virchow and Munter confirmed the paralyzing action was limited to voluntary muscles.[2]

Etymology[edit]

The word "curare" comes from the South American Indian name for the arrow poison, ourare. Presumably, the initial syllable was pronounced with a heavy glottal stroke. Tubocurarine is so-called because the plant samples containing the curare were stored and shipped to Europe in tubes. Likewise, curare stored in calabash containers was called calabash curare.

Use as an anesthetic[edit]

Griffith and Johnson are credited with pioneering the formal clinical introduction of tubocurarine as an adjunct to anesthetic practice on 23 January 1942, at the Montreal Homeopathic Hospital.[3] In this sense, tubocurarine is the prototypical adjunctive neuromuscular non-depolarizing agent. However, others before Griffith and Johnson had attempted use of tubocurarine in several situations:[4][5][6] some under controlled study conditions[7][8] while others not quite controlled and remained unpublished.[9] Regardless, all in all some ~30,000 patients had been given tubocurarine by 1941, although it was Griffith and Johnson's 1942 publication[3] that provided the impetus to the standard use of neuromuscular blocking agents in clinical anesthestic practice - a revolution that rapidly metamorphosized into the standard practice of "balanced" anesthesia: the triad of barbiturate hypnosis, light inhalational anesthesia and muscle relaxation.[10] The technique as described by Gray and Halton was widely known as the "Liverpool technique",[10] and became the standard anesthetic technique in England in the 1950s and 1960s for patients of all ages and physical status. Present clinical anesthetic practice still employs the central principle of balanced anesthesia though with some differences to accommodate subsequent technological advances and introductions of new and better gaseous anesthetic, hypnotic and neuromuscular blocking agents, and tracheal intubation, as well as monitoring techniques that were nonexistent in the day of Gray and Halton: pulse oximetry, capnography, peripheral nerve stimulation, noninvasive blood pressure monitoring, etc.

Chemical properties[edit]

Structurally, tubocurarine is a benzylisoquinoline derivative. For many years, its structure, when first elucidated in 1948,[11] was wrongly thought to be bis-quaternary: in other words, it was thought to be an N,N-dimethylated alkaloid. In 1970, the correct structure was finally established,[12] showing one of the two nitrogens to be tertiary, actually a mono-N-methylated alkaloid.

Biosynthesis[edit]

Tubocurarine biosynthesis involves a radical coupling of the two enantiomers of N-methyl-coclaurine. (R) and (S)-N-methyl-coclaurine come from a Mannich-like reaction between dopamine and 4-hydroxyphenyl-acetaldehyde, facilitated by norcoclaurine synthase (NCS). Both dopamine and 4-hydroxyphenylacetyladehyde originate from L-tyrosine. Methylation of the amine and hydroxyl substituents are facilitated by S-adenosyl methionine (SAM).[13]

Tubocurarine proposed biosynthesis

Biological effects[edit]

Acetylcholine in the synaptic gap[14]

Without intervention, acetylcholine (Ach) in the peripheral nervous system activates skeletal muscles. Acetylcholine is produced in the body of the neuron by choline acetyltransferase and transported down the axon to the synaptic gap. Tubocurarine chloride acts as an antagonist for the nicotinic acetylcholine receptor (nAchr), meaning it blocks the receptor site from Ach.[15] This may be due to the quaternary amino structural motif found on both molecules.

Clinical pharmacology[edit]

Unna et al. reported the effects of tubocurarine on humans:

"Forty-five seconds after the beginning of the injection, heaviness of the eyelids and transitory diplopia were perceived. At the completion of the injection, diplopia became fixed, but could be noticed only when the subject’s eyelids were raised by the operator. As curarization proceeded, it seemed to the subject as if the facial muscles, those of the tongue, pharynx, and lower jaw, the muscles of the neck and back, and the muscles of the extremities became relaxed in about that order. Accompanying the paralysis of the pharynx and the jaw muscles, inability of the subject to swallow was noted … Shortly after the injection was completed the subjects experienced a sensation of increased difficulty in breathing, as if an extra effort was necessary to maintain an adequate respiratory exchange. This sensation was present even though there was no objective evidence of impaired oxygenation or of carbon dioxide retention. It reached its maximum about five minutes after the injection, coinciding with the maximum depression of the vital capacity. In the majority of the experiments the respiratory rate was increased by about 50-100 per cent the first minutes after the injection of any one of the drugs while the tidal volume decreased.”[16]

Tubocurarine has a time of onset of around 5 minutes which is relatively slow among neuromuscular-blocking drugs, and has a duration of action of 60 to 120 minutes.[17][18] It also causes histamine release,[19] now a recognized hallmark of the tetrahydroisioquinolinium class of neuromuscular blocking agents. Histamine release is associated with bronchospasms, hypotension, salivary secretions, making it dangerous for asthmatics, children, and those who are pregnant or lactating.[20] However, the main disadvantage in the use of tubocurarine is its significant ganglion-blocking effect,[21] that manifests as hypotension,[22] in many patients; this constitutes a relative contraindication to its use in patients with myocardial ischaemia.

Because of the shortcomings of tubocurare, much research effort was undertaken soon after its clinical introduction to find a suitable replacement. The efforts unleashed a multitude of compounds borne from structure-activity relations developed from the tubocurare molecule. Some key compounds that have seen clinical use are identified in the muscle relaxants template box below. Of the many tried as replacements, only a few enjoyed as much popularity as tubocurarine: pancuronium, vecuronium, rocuronium, atracurium, and cisatracurium. Succinylcholine is a widely used paralytic drug which acts by activating, instead of blocking, the ACh receptor.

The potassium channel blocker tetraethylammonium (TEA) has been shown to reverse the effects of tubocurarine. It is thought to do so by increasing ACh release, which counteracts the antagonistic effects of tubocurarine on the ACh receptor.

Use as spider bite treatment[edit]

Spiders of the genus Latrodectus have α-latrotoxin in their venom. The most well known spider in this genus is the Black Widow Spider. α-latrotoxin causes the release of neurotransmitters into the synaptic gap, including acetylcholine.[23] Bites are usually not fatal, but do cause a significant amount of pain in addition to muscle spasms. The venom is the most damaging to nerve endings, but the introduction of d-tubocurarine chloride blocks the nAchr, alleviating pain and muscle spasms while its antivenom can be administered.[24]

Toxicology[edit]

An individual administered tubocurarine chloride will be unable to move any voluntary muscles, including the diphragm. A large enough dose will therefore result in death from respiratory failure unless artificial ventilation is initiated. The LD50 for mice and rabbits are 0.13 mg/kg and 0.146 mg/kg intravenously, respectively.[25]

References[edit]

  1. ^ Bernard C (1856). "Analyse physiologie des propriétés des actions de curare et de la nicotine sure systèmes musculaire et nerveux au moyen du curare". Compt. Rend. 43: 305–319. 
  2. ^ Bechter AM (1977). "The civilizing of curare: a history of its development and introduction into anesthesiology". Anesth Analg 56 (2): 305–319. doi:10.1213/00000539-197703000-00032. PMID 322548. 
  3. ^ a b Griffith HR, Johnson GE (1942). "The use of curare in general anesthesia". Anesthesiol 3 (4): 418–420. doi:10.1097/00000542-194207000-00006. 
  4. ^ Läwen A (1912). "Ueber die verbindung der lokakanaesthesie und epidurale injektion anesthesiernder losungen bei tabischen magenkrisen". Beitr Klin Chir 80: 168–189. 
  5. ^ Wilkinson DJ (1991). "Dr. F.P. de Caux - the first user of curare for anaesthesia in England". Anaesthesia 46 (1): 49–51. doi:10.1111/j.1365-2044.1991.tb09317.x. PMID 1996757. 
  6. ^ Bennett AE (1941). "Curare: a preventive of traumatic complications in electroconvulsive shock therapy". Am J Psychiatry 97: 1040–1060. 
  7. ^ West R (1984). "An excursion into pharmacology: curare in medicine". Medical History 28 (4): 391–405. doi:10.1017/s0025727300036279. PMC 1140012. PMID 6390032. 
  8. ^ Burman MS (1939). "Therapeutic use of curare and erythroidine hydrochloride for spastic and dystonic states". Arch Neurol Psychiat 41: 307–327. doi:10.1001/archneurpsyc.1939.02270140093008. 
  9. ^ Bevan DR. (1992) "Curare". In: Maltby JR, Shephard DAE (Eds.), Harold Griffith - His Life and Legacy; Suppl. to Can J Anaesth Vol. 39 (1); 49-55.
  10. ^ a b Gray TC, Halton J (1946). "Technique for the use of d-tubocurarine chloride with balanced anaesthesia". Br Med J 2: 293–295. PMID 20996123. 
  11. ^ King H (1948). "64. Curare alkaloids. Part VII. Constitution of dextrotubocurarine chloride". J Chem Soc: 265. doi:10.1039/jr9480000265. 
  12. ^ Everett AJ, Lowe LA, Wilkinson S (1970). J Chem Soc, Chem Commun: 1020.  Missing or empty |title= (help)
  13. ^ Dewick, P. M. Medicinal Natural Products; a Biosynthetic Approach. 3rd ed.; John Wiley and Sons Ltd.: 2009.
  14. ^ Katzung BG (2001). Basic and clinical pharmacology:Introduction to autonomic pharmacology (8 ed.). The McGraw Hill Companies. pp. 75–91. ISBN 978-0-07-160405-5. 
  15. ^ Wenningmann I, Dilger JP (October 2001). "The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium". Molecular Pharmacology 60 (4): 790–6. PMID 11562442. 
  16. ^ Unna, K. R. (March 1950). "EVALUATION OF CURARIZING DRUGS IN MAN". The Journal of Pharmacology and Experimental Therapeutics 98. 
  17. ^ Thompson MA (1980). "Muscle relaxant drugs". Br J Hosp Med 23 (2): 153–4, 163–4, 167–8 passim. PMID 6102875. 
  18. ^ Page 151 in: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. OCLC 51622037. 
  19. ^ Maclagen J. (1976) In: Zaimis E. (Ed.), "Neuromuscular Junction". Hand. Exp. Pharm.; Vol. 42; Springer-Verlag, Berlin: 421-486.
  20. ^ "d-Tubocurarine (Prototype Nondepolarizing Neuromuscular Blocker)". Tulane University. Retrieved 4 May 2015. 
  21. ^ Bowman WC, Webb SN (1972). "Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat". J Pharm Pharmacol 24 (10): 762–72. doi:10.1111/j.2042-7158.1972.tb08880.x. PMID 4403972. 
  22. ^ Coleman AJ, Downing JW, Leary WP, Moyes DG (1972). "The immediate cardiovascular effects of pancuronium, alcuronium and tubocurarine in man". Anaesthesia 27 (4): 415–22. doi:10.1111/j.1365-2044.1972.tb08247.x. PMID 4264060. 
  23. ^ Südhof, Thomas C (March 2001). "α-LATROTOXIN AND ITS RECEPTORS: Neurexins and CIRL/Latrophilins". Annual Review of Neuroscience 24: 933-962. 
  24. ^ Allen, George W. (1953). "BLACK WIDOW SPIDER (LATRODECTUS MACTANS) POISONING TREATED WITH D-TUBOCURARINE CHLORIDE". Annals of Internal Medicine 3: 624-625. doi:10.7326/0003-4819-39-3-624. 
  25. ^ Gesler, H. M.; Hoppe, James O. (1956). "3,6-BIS(3-DIETHYLAMINOPROPOXY) PYRIDAZINE BISMETHIODIDE, A LONG-ACTING NEUROMUSCULAR BLOCKING AGENT". The Journal of Pharmacology and Experimental Therapeutics 118. 

External links[edit]